Sanjivani Paranteral Q1 FY27: Recovery quarter, with IV fluids scaling into a second engine

Q1 FY27 consolidated revenue from operations was INR 238.39 million, EBITDA including other income was INR 43.21 million (18.01% margin on total income), and PAT was INR 24.91 million (10.38% margin).

The presentation describes four verticals: injectables, oral formulations (tablets and capsules), IV fluids via SPL Infusion (subsidiary), and nutraceuticals via the Prague JV (Alevia Healthcare).

Management guides FY27 base business revenue of INR 800 to 850 million and Pune IV-fluid business revenue of INR 600 to 650 million.

Guided utilisation ramp is 40% in Q1 FY27, 45% in Q2 FY27, 60% in Q3 FY27 and 70% in Q4 FY27.

The presentation states March 2026 saw no major export shipments due to route disruption; the company activated alternate routes via Saudi Arabia to Turkey and Southeast Asia and restored shipments, expecting recovery from Q1 FY27.

FY26 export share is stated as 78.5% of revenue. Region mix in FY26 is shown as Middle East and Africa 41.7%, Latin America 32.7%, India and Subcontinent 23.0%, and CIS 2.6%.